NASDAQ: PTCT · Biotechnology
PTC Therapeutics (PTCT) fair value and price range
As of 26 Sep 2026, Faircurve's model values PTC Therapeutics (PTCT) at $71.64 a share. The stock last closed at $63.46, which puts the model's fair value 12.9% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 2 Oct 2026. PTC Therapeutics, Inc.
Faircurve Insights · 26 Sep 2026
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company that researches, develops, and commercialises innovative therapies for patients with rare genetic disorders.
Faircurve's model found a fair value of $71.64 a share on 26 Sep 2026, the midpoint of 2,000 simulations. This fair value moved -4.2% since the previous run, on 19 Sep 2026, which gave $74.76. The model's calibrated range over 63 trading days is $60.10 to $87.35, built from the fair value, and held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low.
The overall quality score against comparable companies is 45 out of 100. The model compares it with Acadia Pharmaceuticals Inc. (ACAD), Arcus Biosciences, Inc. (RCUS), and TG Therapeutics, Inc. (TGTX). The moves around the last 8 earnings reports range from -11.6% to +16.0%, with a median size of 8.6%, ignoring direction.
Written from the figures on this page for the 26 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give PTCT?
The calibrated range for PTCT over 63 trading days is $60.10 to $87.35. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $56.32 to $90.92. In 67% of the simulations the fair value came out above the price the model ran on.
How does PTCT score on business quality?
PTC Therapeutics's overall quality score is 45 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 35 | -14.6%ROIC | 9.9% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 49 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 58 | 114.5%Revenue growth, trailing | 60.6% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 21 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 61 | -2.04xNet debt / EBITDA | 1.10x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 45 | 24.2 ptsEBITDA margin downside volatility, 5y | 64.9 pts |
How does PTCT compare with similar companies?
The companies in biotechnology closest to PTC Therapeutics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| LGND Ligand Pharmaceuticals Incorporated | $302.96 | $302.87 | 0.0% | Low evidence grade |
| ACAD Acadia Pharmaceuticals Inc. | $19.95 | $23.69 | +18.7% | Undervalued |
| CYTK Cytokinetics, Incorporated | $65.60 | $55.66 | -15.2% | Low evidence grade |
| RCUS Arcus Biosciences, Inc. | $24.44 | $21.87 | -10.5% | Fairly valued |
| TGTX TG Therapeutics, Inc. | $54.29 | $67.07 | +23.5% | Undervalued |
| PTGX Protagonist Therapeutics, Inc. | $140.06 | $142.28 | +1.6% | Data under review |
| ARWR Arrowhead Pharmaceuticals, Inc. | $64.19 | $62.14 | -3.2% | Data under review |
| KRYS Krystal Biotech, Inc. | $322.28 | $387.29 | +20.2% | Low evidence grade |
When does PTCT report earnings, and how has the stock reacted?
PTC Therapeutics's next earnings report is scheduled for 3 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 15.4% in either direction through the nearest expiry, about 48 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How PTCT moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 8.6%.
| Report date | Two session move |
|---|---|
| 30 Jul 2026 | -8.7% |
| 7 May 2026 | +10.7% |
| 19 Feb 2026 | +2.5% |
| 4 Nov 2025 | +5.7% |
| 7 Aug 2025 | -11.6% |
| 6 May 2025 | +16.0% |
| 27 Feb 2025 | +8.4% |
| 7 Nov 2024 | +2.5% |
PTC Therapeutics at a glance
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders.
- Market value
- $5.2B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $1.3B
- Consensus revenue growth, next fiscal year
- -27.3%
- Analysts with estimates
- 7
- Beta to the US market
- 0.51
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices PTC Therapeutics on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for PTCT was $74.76. As of 26 Sep 2026 it is $71.64, a change of -4.2%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about PTC Therapeutics's valuation
Is PTC Therapeutics stock undervalued or overvalued?
Faircurve's model puts PTCT's fair value at $71.64 a share against a last close of $63.46, as of 26 Sep 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is PTCT's fair value?
$71.64 a share as of 26 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $56.32 to $90.92.
What price range does the model give PTCT?
$60.10 to $87.35 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does PTC Therapeutics report earnings next?
The next report is scheduled for 3 Nov 2026. Companies can move their dates.
How much has PTCT moved on past earnings reports?
Across its last 8 reports the median two session move was 8.6%, ignoring direction. The largest was +16.0% around the report of 6 May 2025.
How confident is the model in this valuation?
The model's evidence grade for PTCT is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.